Previous findings from the CO-MED trial suggested better outcomes for a bupropion–SSRI combination compared with SSRI monotherapy in participants with extreme obesity (BMI ≥ 35 kg/m2)16 and higher baseline CRP.20 More studies are needed to further replicate these findings. Here, CRP is linked to obesity due to melanocortin 4 receptor deficiency.